How Collaborative Value Engineering and Continuous Improvement Enhance the CDMO Relationship

Drug product

The search for vaccines and treatments throughout the COVID-19 pandemic, combined with the backlog of non-COVID therapies that piled up during the pandemic’s initial months, has driven a surge in demand for contract development and manufacturing organization (CDMO) production capacity. As CDMOs have transformed to meet that need — adding new facilities and equipment, as well as introducing operational strategies to overcome burdens related to the pandemic — the challenge for commercial pharmaceutical companies has evolved from simply finding a CDMO partner with adequate capacity. Pharmaceutical companies now require a rightsized partner that shares similar values and vision, as well as an understanding of the competitive hurdles and market dynamics they must navigate.

Download this whitepaper to learn more about how a collaborative partnership model is effective in optimizing profitability management and product life cycles.

Be the first to receive our latest news and updates